Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Medicinal & Biomolecular Chemistry
Rank in SubField 1: 4,482 out of 334,837 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 116,367 | 116,427 |
| Total Cites | 8,115 | 9,702 |
| H-index | 50 | 56 |
| Hm-index | 19 | 21 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 60 | 60 |
| Number of Single+First Authored Papers | 17 | 17 |
| Total Cites to Single+First Authored Papers | 218 | 235 |
| Number of Single+First+Last Authored Papers | 124 | 124 |
| Total Cites to Single+First+Last Authored Papers | 4,433 | 5,005 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 5,771 | 6,355 |
| Ratio of Total Citations to Distinct Citing Papers | 1.41 | 1.53 |
| Self-Citation Percentage |
16.36%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Medicinal & Biomolecular Chemistry
Rank in SubField 1: 4,425 out of 312,644 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 113,367 | 113,460 |
| Total Cites | 7,499 | 9,113 |
| H-index | 50 | 55 |
| Hm-index | 18 | 20 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 55 | 55 |
| Number of Single+First Authored Papers | 17 | 17 |
| Total Cites to Single+First Authored Papers | 213 | 230 |
| Number of Single+First+Last Authored Papers | 124 | 124 |
| Total Cites to Single+First+Last Authored Papers | 4,211 | 4,793 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 5,345 | 5,915 |
| Ratio of Total Citations to Distinct Citing Papers | 1.40 | 1.54 |
| Self-Citation Percentage |
17.71%
|
|
de Witte, Peter
Departement Farmaceutische en Farmacologische Wetenschappen,
Belgium
2022 Rank: 110,861
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Medicinal & Biomolecular Chemistry
Rank in SubField 1: 4,327 out of 293,195 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 110,861 | 110,940 |
| Total Cites | 6,904 | 8,410 |
| H-index | 47 | 53 |
| Hm-index | 18 | 20 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 52 | 52 |
| Number of Single+First Authored Papers | 17 | 17 |
| Total Cites to Single+First Authored Papers | 204 | 221 |
| Number of Single+First+Last Authored Papers | 124 | 124 |
| Total Cites to Single+First+Last Authored Papers | 3,976 | 4,526 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4,866 | 5,389 |
| Ratio of Total Citations to Distinct Citing Papers | 1.42 | 1.56 |
| Self-Citation Percentage |
17.91%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Pharmacology & Pharmacy
Rank in SubField 1: 4,335 out of 271,773 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 110,697 | 110,278 |
| Total Cites | 6,550 | 8,013 |
| H-index | 45 | 51 |
| Hm-index | 17 | 19 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 50 | 50 |
| Number of Single+First Authored Papers | 17 | 17 |
| Total Cites to Single+First Authored Papers | 202 | 218 |
| Number of Single+First+Last Authored Papers | 124 | 124 |
| Total Cites to Single+First+Last Authored Papers | 3,839 | 4,376 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4,620 | 5,117 |
| Ratio of Total Citations to Distinct Citing Papers | 1.42 | 1.57 |
| Self-Citation Percentage |
18.26%
|
|
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.